Biotechnologies Assets SA (BST.MC)

EUR 0.29

(-5.84%)

EBITDA Summary of Biotechnologies Assets SA

  • Biotechnologies Assets SA's latest annual EBITDA in 2023 was 5.09 Million EUR , down -97.58% from previous year.
  • Biotechnologies Assets SA's latest quarterly EBITDA in 2023 FY was N/A , down -97.58% from previous quarter.
  • Biotechnologies Assets SA reported an annual EBITDA of 450.39 Thousand EUR in 2022, up 974525.85% from previous year.
  • Biotechnologies Assets SA reported an annual EBITDA of -25.03 Thousand EUR in 2021, down -97.8% from previous year.
  • Biotechnologies Assets SA reported a quarterly EBITDA of 1.8 Million EUR for 2023 Q2, down 0.0% from previous quarter.
  • Biotechnologies Assets SA reported a quarterly EBITDA of 52.57 Thousand EUR for 2023 Q3, down -97.09% from previous quarter.

Annual EBITDA Chart of Biotechnologies Assets SA (2023 - 2010)

Historical Annual EBITDA of Biotechnologies Assets SA (2023 - 2010)

Year EBITDA EBITDA Growth
2023 5.09 Million EUR -97.58%
2022 450.39 Thousand EUR 974525.85%
2021 -25.03 Thousand EUR -97.8%
2020 993.11 Thousand EUR 167.5%
2019 1.75 Million EUR 86.72%
2018 -11.07 Million EUR -1134.42%
2017 -10.19 Million EUR 175.74%
2016 -459.74 Thousand EUR 2386.94%
2015 42.28 Thousand EUR -98.4%
2014 1.59 Million EUR 19.16%
2013 818.25 Thousand EUR 432.21%
2012 -246.3 Thousand EUR -211.91%
2011 220.09 Thousand EUR 216.03%
2010 -189.68 Thousand EUR 0.0%

Peer EBITDA Comparison of Biotechnologies Assets SA

Name EBITDA EBITDA Difference
Atrys Health, S.A. 31.91 Million EUR 84.023%
Oryzon Genomics S.A. -4.43 Million EUR 215.013%
Pharma Mar, S.A. 4.54 Million EUR -12.089%
Laboratorios Farmaceuticos Rovi, S.A. 245.81 Million EUR 97.926%